Pfizer Tops Estimates as Investors Await Possible Breakup

Pfizer Inc., the world’s biggest drugmaker, reported third-quarter profit that beat analysts’ estimates as the company cut costs and sales of its top vaccine and pain drugs increased.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.